Product Information
MINOCYCLINE 50 MG CAPSULE is a generic product labeled by Actavis Pharma, Inc., priced at $0.1801 per EA under NDC 00591569401. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Dec 30, 1991. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
50 mg/1
Manufacturer
Actavis Pharma, Inc.NDC
00591569401
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
MINOCYCLINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA063181FDA Approved
12/30/1991
TE Code
AB
On Market Since
2/1/1992
Pharmacological Classes
Price Statistics
The NADAC for MINOCYCLINE 50 MG CAPSULE has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 38.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1801 per EA |
|---|---|
| All-time high | $0.2619 (Aug 16, 2017) |
| All-time low | $0.1298 (Nov 28, 2013) |
| 52-week high | $0.1814 |
| 52-week low | $0.1748 |
| Median price | $0.1975 |
| Average price | $0.1941 |
| Largest weekly change | +39.9% (Dec 17, 2014) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 2% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Actavis Pharma, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Minocycline Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Tetracycline-class Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MINOCYCLINE 50 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for MINOCYCLINE 50 MG CAPSULE, manufactured by Actavis Pharma, Inc., is $0.1801 per EA (NDC 00591569401), effective Sep 30, 2026.
How has the price of MINOCYCLINE 50 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for MINOCYCLINE 50 MG CAPSULE has risen 38.8%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for MINOCYCLINE 50 MG CAPSULE?
Since Nov 28, 2013, the NADAC for MINOCYCLINE 50 MG CAPSULE has ranged from a low of $0.1298 (Nov 28, 2013) to a high of $0.2619 (Aug 16, 2017), with a median of $0.1975 per EA.
Are there cheaper alternatives to MINOCYCLINE 50 MG CAPSULE?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, MINOCYCLINE 50 MG CAPSULE, is $0.1757 per EA — about 2% below MINOCYCLINE 50 MG CAPSULE.
Who manufactures MINOCYCLINE 50 MG CAPSULE?
MINOCYCLINE 50 MG CAPSULE (NDC 00591569401) is labeled by Actavis Pharma, Inc., and CMS classifies it as a generic product.